Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

Five Facts about mental health

May 21, 2025 Medical Communications, Medical Education, Research and Development European Commission, Pharmacy, Psychiatry, mental health, mental health condition

32% of people suffer from at least one mental health issue, with daily struggles like financial and job insecurity being …
Feature
researchers

Novartis releases new data across oncology and haematology pipelines

May 21, 2025 Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology

Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …
News

Slingshot Therapeutics appoints Ed Savory as head of chemistry

May 21, 2025 Research and Development Corporate, Pharmacy, Slingshot Therapeutics, appointment

Slingshot Therapeutics has announced the appointment of Ed Savory as head of chemistry. He will oversee the company’s chemistry strategy …
Appointment

BioPhorum appoints Uwe Buecheler as non-executive director

May 21, 2025 Medical Communications, Research and Development BioPhorum, Corporate, appointment, biopharma, medical communication

BioPhorum has announced the appointment of Uwe Buecheler as a non-executive director to its board. The company brings together leaders …
Appointment

Multiple myeloma treatment approved in Japan

May 21, 2025 Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …
News

FDA approves Incyte’s new anal cancer treatment

May 20, 2025 Research and Development FDA, Incyte Corporation, Oncology, Orphan Drug Designation (ODD), Zynyz, fast track designation, priority review

The US Food and Drug Administration (FDA) has approved Incyte Corporation’s immunotherapy retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel to treat …
News

Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions

May 20, 2025 Research and Development Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology

Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off …
News

FDA approves diagnostic tool for MET-targeted lung cancer therapy

May 19, 2025 Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer

The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …
News

Cold plasma therapy shown to be 100% effective against pneumonia-causing bacteria

May 19, 2025 Research and Development Infections and infestations, MRSA, Viromed Medical, intensive care, lung therapy, ventilator-associated pneumonia (VAP)

A breakthrough in lung therapy has been reported by German biotech company Viromed Medical whose cold plasma treatment has demonstrated …
News

Medable unveils oncology trial platform aimed at reducing logistical hurdles

May 16, 2025 Biotech/start-up, Business Services, Research and Development, Sales and Marketing, Technical Consultancy AI, FDA, Medable, Oncology, digital platform, oncology research, oncology trials

Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical trials by addressing growing operational …
News
researchers

Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU

May 16, 2025 Research and Development Clinical Trial Application (CTA), European Union (EU), FDA, Food and Drug Administration, Moleculin Biotech, Oncology, Orphan Drug Designation (ODD), acute myeloid leukaemia

Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine …
News

Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome

May 15, 2025 Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases

Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
News

Kaerus Bioscience secures FDA approval for rare genetic disorder treatment

May 15, 2025 Research and Development FDA, Fragile X syndrome, Kaerus Bioscience, Orphan Drug Designation (ODD), Rare Diseases, Rare Pediatric Drug Designations (RPDD), genetic syndromes

Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Drug …
News
handshake_2

Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement

May 14, 2025 Research and Development Corporate, Cure.Bio Portfolio Company, Pharmacy, Secarna Pharmaceuticals, agreement

Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate …
News

Tozaro forms Technical Advisory Board to accelerate Smart Polymer commercialisation for CGT bioprocessing

May 14, 2025 Manufacturing and Production, Research and Development CGT production, Cell and Gene Therapy (CGT), Contraception, Pharmacy, Tozaro, advisory board

Tozaro, a UK-based biopharma focused on cell and gene therapy (CGT), has announced the formation of a Technical Advisory Board …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026